论文部分内容阅读
目的:观察眼前房注射Bevacizumab(avastin)对虹膜红变的疗效及安全性。方法:5例(5眼)虹膜红变者分别继发于糖尿病视网膜病变,静脉周围炎,静脉阻塞。其中2例为玻璃体切割术后硅油填充眼,给予前房注射0.03ml(0.75mg)Bevacizumb(avastin)。其中1例联合小梁切除手术,1例联合睫状体冷凝术。结果:所有手术眼虹膜新生血管迅速消退,眼内压在联合使用抗青光眼手术或药物后降低,随访2~5mo没有虹膜红变复发,眼内压控制良好。结论:前房注射Bevacizumab(avastin)有效地减轻了虹膜红变,特别是在一些不适合玻璃体腔注射的病例,短期的研究随访证实前房注射迅速消退虹膜新生血管且无明显副作用。
Objective: To observe the efficacy and safety of anvular injection of Bevacizumab (avastin) on iris redistribution. Methods: Five cases (5 eyes) of iris-red cells were secondary to diabetic retinopathy, peri-venous inflammation and vein occlusion. Two of them were filled with silicone oil after vitrectomy and anterior chamber injection of Bevacizumb (avastin) (0.03ml, 0.75mg) was given. One case of trabeculectomy combined with ciliary body condensation in 1 case. Results: The iris neovascularization of all eyes retreated rapidly. The intraocular pressure was decreased after combined use of anti-glaucoma surgery or drugs. No recurrence of iris redness was observed during 2 to 5 months of follow-up. Intraocular pressure was well controlled. CONCLUSION: Anterior chamber injection of avastin is effective in reducing iris redisation, especially in some cases unsuitable for intravitreal injection. Short-term follow-up confirmed that anterior chamber injection quickly abolished iris neovascularization with no apparent side effects.